Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totaling 5,179 shares, a growth of 154.7% from the June 30th total of 2,033 shares. Based on an average trading volume of 869 shares, the days-to-cover ratio is currently 6.0 days.
Algernon Pharmaceuticals Price Performance
Algernon Pharmaceuticals stock opened at $0.30 on Wednesday. Algernon Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $0.64. The firm has a fifty day moving average price of $0.31 and a two-hundred day moving average price of $0.16.
About Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.
The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).
Featured Stories
- Five stocks we like better than Algernon Pharmaceuticals
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
